Eli Lilly posts strong Q3 results, raises 2025 outlook, and expands patient access to its weight-loss drug Zepbound.
Probe by former Special Counsel Jack Smith targets over 430 Republicans, raising concerns about political surveillance and partisan 'fishing expedition'.
Carlsberg's Q3 revenue rises 17.8% driven by acquisitions, but organic revenue and volumes decline amid challenging market conditions.
Eli Lilly posts strong Q3 results, raises 2025 outlook, and expands patient access to its weight-loss drug Zepbound.
Probe by former Special Counsel Jack Smith targets over 430 Republicans, raising concerns about political surveillance and partisan 'fishing expedition'.
Carlsberg's Q3 revenue rises 17.8% driven by acquisitions, but organic revenue and volumes decline amid challenging market conditions.